NEW YORK, March 20, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding OPKO Health, Inc. (NYSE: OPK), Synageva BioPharma Corp. (NASDAQ: GEVA), Hill-Rom Holdings, Inc. (NYSE: HRC), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), and Cardiovascular Systems Inc. (NASDAQ: CSII). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Opko Health, Inc. Analyst Notes
On March 10, 2014, OPKO Health, Inc. (OPKO) reported that one of its divisions, OPKO Diagnostics, has signed a supply agreement with Sony DADC for high volume production of a key component of the OPKO Sangia™ microfluidic cassette. The Company informed that the Sangia cassettes are designed to perform quantitative immunoassays from a finger-stick blood sample on the Claros®1 in-office analyzer. Commenting on the agreement, David Okrongly, President of OPKO Diagnostics, stated, "We are pleased to be partnered with Sony DADC, a world leader in high precision consumable manufacturing, for production of Sangia technology components. It is critical to us that Sony DADC also meets the regulatory demands of our in vitro diagnostic products and is manufacturing to the ISO 13485 quality standard." The Company added that Sony DADC BioSciences is using ISO 13485 facility in Salzburg, Austria to manufacture to OPKO Diagnostics' specifications. The full analyst notes on OPKO Health, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03202014/OPK/report.pdf
Synageva BioPharma Corp. Analyst Notes
On March 4, 2014, Synageva BioPharma Corp. (Synageva) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,663,631 covering methods of treating lysosomal acid lipase deficiency (LAL Deficiency). According to the Company, the patent provides protection until 2031, not including any patent term extension, and complements Synageva's existing and planned global patent portfolio covering its LAL Deficiency program, which includes intellectual property directed to composition of matter, methods of use, and manufacturing. The full analyst notes on Synageva BioPharma Corp. are available to download free of charge at:
http://www.AnalystsReview.com/03202014/GEVA/report.pdf
Hill-Rom Holdings, Inc. Analyst Notes
On March 10, 2014, Hill-Rom Holdings, Inc. (Hill-Rom) announced the election of William G. Dempsey to the Company's Board of Directors. The Company stated that Mr. Dempsey currently serves as a director of Landauer, Inc., Nordion Inc., and Hospira, Inc., and previously held various executive positions with Abbott Laboratories. Commenting on the appointment, Rolf A. Classon, Chairman of the Hill-Rom Board of Directors, stated, "Bill has a wealth of experience in the health care industry that will further strengthen our Board. His broad senior level executive, international and operational experience will serve our shareholders and Board well." The full analyst notes on Hill-Rom Holdings, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03202014/HRC/report.pdf
Anacor Pharmaceuticals, Inc. Analyst Notes
On March 10, 2014, Anacor Pharmaceuticals, Inc. (Anacor) announced that it has appointed Vince Ippolito as the Company's Executive Vice President and Chief Commercial Officer. David Perry, CEO of Anacor, commented, "We are very excited to have Vince join our team as Chief Commercial Officer. His extensive experience in launching new products and leading sales and marketing efforts to specialty physicians will be invaluable as we develop a commercial strategy for tavaborole and AN2728." The Company informed that Mr. Ippolito has over 25 years of experience in leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc., Medicis Pharmaceutical Corporation, and Novartis AG. The full analyst notes on Anacor Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03202014/ANAC/report.pdf
Cardiovascular Systems Inc. Analyst Notes
On March 10, 2014, Cardiovascular Systems Inc. (Cardiovascular Systems) announced that it has obtained FDA clearance of its Diamondback 360® 60cm Peripheral Orbital Atherectomy Systems (OAS) for treating peripheral arterial disease (PAD). Commenting on the clearance, David L. Martin, Cardiovascular Systems President and CEO, stated, "Receiving FDA clearance for our new 60cm, 4 French (4 Fr) devices demonstrates CSI's commitment to advancing technology and expanding the interventional market. Our new 60cm Diamondback devices are compatible with 4 Fr introducer sheaths. The use of smaller sheaths has been shown to reduce procedure times, enable quicker patient recovery and have less procedural complications from bleeding, providing additional procedural benefits to patients and physicians." The full analyst notes on Cardiovascular Systems Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03202014/CSII/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review
